Products
Online Inquiry
Our Products Cannot Be Used As Medicines Directly For Personal Use.
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
YO-01027
Cat No.
CEI-0205
Description
YO-01027 (Dibenzazepine, DBZ) can inhibit gamma-secretase with IC50 of 2.6 nM.
CAS No.
209984-56-5
Molecular Weight
463.48
Purity
>99%
Storage
2 years at -20 centigrade
Targets
gamma-secretase
Molecular Formula
C26H23F2N3O3
Chemical Name
7-(S)-[N(3,5-difluorophenylacetyl)-L-alaninyl]amino-5-methyl-5,7-dihydro-6H-dibenz[b,d]azepin-6-one
Solubility
DSMO 93 mg/mL Water
In vitro
YO-01027 (Dibenzazepine, DBZ) administered to APPL- or Notch-expressing cells leads to the progressive accumulation of APPL CTF fragments and a decrease in NICD production in a strictly dose-dependent manner.As a gamma-secretase inhibitor, YO-01027 (Dibenzazepine, DBZ) is more potent than CpnE, DAPT, and DFK167.YO-01027 (Dibenzazepine, DBZ) showed no apparent discrimination in blocking APPL and Notch cleavages.
In vivo
In vivo, YO-01027 (Dibenzazepine, DBZ) significantly decrease MCF7 but not MDA-MB-231 tumours and increase latency compared to control mice (18 to 28 days). YO-01027 (Dibenzazepine, DBZ)-treated MCF7 tumours that did form had significantly reduced tumour volumes.
Download
Download Datasheet